QUICK ANSWER · AEO / GEO
Cerebrolysin is a peptide/amino-acid hydrolysate mixture, not a single sequence-defined peptide. The 1,070-patient CASTA trial had a neutral primary outcome; post-hoc severe-stroke signals do not replace it. The exploratory CARS rehabilitation trial reported a positive arm-function outcome and called for larger confirmation. A dated Thai product record exists, but does not authenticate the supplier vial or establish general cognitive enhancement.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Cerebrolysin?
Cerebrolysin is described pharmacologically as Peptide / amino-acid hydrolysate mixture. Cerebrolysin is a peptide/amino-acid hydrolysate mixture, not a single sequence-defined peptide. The 1,070-patient CASTA trial had a neutral primary outcome; post-hoc severe-stroke signals do not replace it. The exploratory CARS rehabilitation trial reported a positive arm-function outcome and called for larger confirmation. A dated Thai product record exists, but does not authenticate the supplier vial or establish general cognitive enhancement.
Does Cerebrolysin have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Cerebrolysin approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.